Table 1

Fhit reactivity in stage I NSCLC tumors according to clinicopathological features of patients

TotalFhit reactivity
Negative (%)Positive (%) P
Age
 Mean age64.0 yrs
 Age range39–83 yrs
 Age < 60 yrs25 patients16 (64%)9 (36%)0.08a
 Age ≥ 60 yrs62 patients27 (44%)35 (56%)
Sex
 Male62 patients32 (52%)30 (48%)0.52b
 Female25 patients11 (44%)14 (56%)
Smoking history
 Smokers76 patients39 (51%)37 (49%)0.68c
 Nonsmokers6 patients2 (33%)4 (67%)
 Data not available5 patients2 (40%)3 (60%)
Histology of tumors
 Adenocarcinoma37 patients17 (46%)20 (54%)0.29d
 Squamous cell carcinoma36 patients21 (58%)15 (42%)
 Bronchoalveolar8 patients1 (13%)7 (87%)
 Large cell carcinoma3 patients2 (67%)1 (33%)
 Adenosquamous1 patient1 (100%)0 (0%)
 Unclassified2 patients1 (50%)1 (50%)
5-year-survival
 OS87 patients60%50%0.368
 DFS86 patientse70%65%0.69
  • a P for the comparison between the percentage of Fhit negativity in younger patients versus older patients.

  • b P for the comparison between the percentage of Fhit negativity in males versus females.

  • c P for the comparison between the percentage of Fhit negativity in smokers versus nonsmokers.

  • d P for the comparison between the percentage of Fhit negativity in adenocarcinoma versus squamous cell carcinoma.

  • e One patient whose medical record was not available for determination of DFS was excluded from the analysis.